Finance Watch: Public Companies Pursue All Options To Fund R&D, Launches
Immunome, Morphimmune Merge, Close $125m PIPE
Executive Summary
Public Company Edition: Follow-on offerings may not be the favored path to funding development programs or product launches after major milestones in the current environment. Amicus secured $430m in a deal with Blackstone, while OPKO’s Modex garnered up to $168m from BARDA.